240 related articles for article (PubMed ID: 34899596)
21. Challenges in Orphan Drug Development: Identification of Effective Therapy for Thyroid-Associated Ophthalmopathy.
Smith TJ
Annu Rev Pharmacol Toxicol; 2019 Jan; 59():129-148. PubMed ID: 30044728
[TBL] [Abstract][Full Text] [Related]
22. Evidence That Graves' Ophthalmopathy Immunoglobulins Do Not Directly Activate IGF-1 Receptors.
Marcus-Samuels B; Krieger CC; Boutin A; Kahaly GJ; Neumann S; Gershengorn MC
Thyroid; 2018 May; 28(5):650-655. PubMed ID: 29631510
[TBL] [Abstract][Full Text] [Related]
23. Adipose tissue depot-specific differences in the regulation of hyaluronan production of relevance to Graves' orbitopathy.
Zhang L; Grennan-Jones F; Lane C; Rees DA; Dayan CM; Ludgate M
J Clin Endocrinol Metab; 2012 Feb; 97(2):653-62. PubMed ID: 22162480
[TBL] [Abstract][Full Text] [Related]
24. Immunopathogenesis of Graves' ophthalmopathy: the role of the TSH receptor.
Iyer S; Bahn R
Best Pract Res Clin Endocrinol Metab; 2012 Jun; 26(3):281-9. PubMed ID: 22632365
[TBL] [Abstract][Full Text] [Related]
25. Modeling Graves' Orbitopathy in Experimental Graves' Disease.
Banga JP; Moshkelgosha S; Berchner-Pfannschmidt U; Eckstein A
Horm Metab Res; 2015 Sep; 47(10):797-803. PubMed ID: 26287396
[TBL] [Abstract][Full Text] [Related]
26. TSH/IGF-1 Receptor Cross-Talk Rapidly Activates Extracellular Signal-Regulated Kinases in Multiple Cell Types.
Krieger CC; Perry JD; Morgan SJ; Kahaly GJ; Gershengorn MC
Endocrinology; 2017 Oct; 158(10):3676-3683. PubMed ID: 28938449
[TBL] [Abstract][Full Text] [Related]
27. Thyrotropin receptor expression in Graves' orbital adipose/connective tissues: potential autoantigen in Graves' ophthalmopathy.
Bahn RS; Dutton CM; Natt N; Joba W; Spitzweg C; Heufelder AE
J Clin Endocrinol Metab; 1998 Mar; 83(3):998-1002. PubMed ID: 9506762
[TBL] [Abstract][Full Text] [Related]
28. Insulin-Like Growth Factor Pathway and the Thyroid.
Smith TJ
Front Endocrinol (Lausanne); 2021; 12():653627. PubMed ID: 34149612
[TBL] [Abstract][Full Text] [Related]
29. Autoimmunity in Graves' ophthalmopathy: the result of an unfortunate marriage between TSH receptors and IGF-1 receptors?
Wiersinga WM
J Clin Endocrinol Metab; 2011 Aug; 96(8):2386-94. PubMed ID: 21677036
[TBL] [Abstract][Full Text] [Related]
30. Cytokines as Targets of Novel Therapies for Graves' Ophthalmopathy.
Fallahi P; Ferrari SM; Elia G; Ragusa F; Paparo SR; Patrizio A; Camastra S; Miccoli M; Cavallini G; Benvenga S; Antonelli A
Front Endocrinol (Lausanne); 2021; 12():654473. PubMed ID: 33935970
[TBL] [Abstract][Full Text] [Related]
31. Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves' disease.
Tsui S; Naik V; Hoa N; Hwang CJ; Afifiyan NF; Sinha Hikim A; Gianoukakis AG; Douglas RS; Smith TJ
J Immunol; 2008 Sep; 181(6):4397-405. PubMed ID: 18768899
[TBL] [Abstract][Full Text] [Related]
32. Arrestin-β-1 Physically Scaffolds TSH and IGF1 Receptors to Enable Crosstalk.
Krieger CC; Boutin A; Jang D; Morgan SJ; Banga JP; Kahaly GJ; Klubo-Gwiezdzinska J; Neumann S; Gershengorn MC
Endocrinology; 2019 Jun; 160(6):1468-1479. PubMed ID: 31127272
[TBL] [Abstract][Full Text] [Related]
33. Expression of Endogenous Putative TSH Binding Protein in Orbit.
Draman MS; Grennan-Jones F; Taylor P; Muller I; Evans S; Haridas A; Morris DS; Rees DA; Lane C; Dayan C; Zhang L; Ludgate M
Curr Issues Mol Biol; 2021 Oct; 43(3):1794-1804. PubMed ID: 34889904
[TBL] [Abstract][Full Text] [Related]
34. Orbital fibrosis in a mouse model of Graves' disease induced by genetic immunization of thyrotropin receptor cDNA.
Zhao SX; Tsui S; Cheung A; Douglas RS; Smith TJ; Banga JP
J Endocrinol; 2011 Sep; 210(3):369-77. PubMed ID: 21715431
[TBL] [Abstract][Full Text] [Related]
35. [The role of adipose tissue in the pathogenesis and clinical manifestation of Graves' orbitopathy].
Janusz P; Pawlak-Adamska E; Kochanowska IE; Daroszewski J
Postepy Hig Med Dosw (Online); 2013 Dec; 67():1173-81. PubMed ID: 24379258
[TBL] [Abstract][Full Text] [Related]
36. A review of TSHR- and IGF-1R-related pathogenesis and treatment of Graves' orbitopathy.
Cui X; Wang F; Liu C
Front Immunol; 2023; 14():1062045. PubMed ID: 36742308
[TBL] [Abstract][Full Text] [Related]
37. Oxidative Stress and Upregulation of Antioxidant Proteins, Including Adiponectin, in Extraocular Muscular Cells, Orbital Adipocytes, and Thyrocytes in Graves' Disease Associated with Orbitopathy.
Marique L; Senou M; Craps J; Delaigle A; Van Regemorter E; Wérion A; Van Regemorter V; Mourad M; Nyssen-Behets C; Lengelé B; Baldeschi L; Boschi A; Brichard S; Daumerie C; Many MC
Thyroid; 2015 Sep; 25(9):1033-42. PubMed ID: 26176182
[TBL] [Abstract][Full Text] [Related]
38. A New Highly Thyrotropin Receptor-Selective Small-Molecule Antagonist with Potential for the Treatment of Graves' Orbitopathy.
Marcinkowski P; Hoyer I; Specker E; Furkert J; Rutz C; Neuenschwander M; Sobottka S; Sun H; Nazare M; Berchner-Pfannschmidt U; von Kries JP; Eckstein A; Schülein R; Krause G
Thyroid; 2019 Jan; 29(1):111-123. PubMed ID: 30351237
[TBL] [Abstract][Full Text] [Related]
39. Pathogenesis of Graves' ophthalmopathy: the role of autoantibodies.
Khoo TK; Bahn RS
Thyroid; 2007 Oct; 17(10):1013-8. PubMed ID: 17935483
[TBL] [Abstract][Full Text] [Related]
40. Bidirectional TSH and IGF-1 receptor cross talk mediates stimulation of hyaluronan secretion by Graves' disease immunoglobins.
Krieger CC; Neumann S; Place RF; Marcus-Samuels B; Gershengorn MC
J Clin Endocrinol Metab; 2015 Mar; 100(3):1071-7. PubMed ID: 25485727
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]